SK bioscience\'s first mRNA vaccine candidate enters Phase 1/2 clinical trials in Australia and New Zealand,with interim results expected by 2026
Transaction Completely and Definitively Transforms Vialto\'s Capital Structure,Delivering a $225 Million New Money Equity Capital Investment in Vialto and a Reduction of Approximately $550 Million of
A survey of 2,000 bank customers reveals that 84% are likely to switch banks to access services that help them reach their financial goals
Partnership combines Galileo\'s technology platform andAscenda\'s loyalty expertise to simplify and power card loyalty programs
ATLANTA,Feb. 25,2025--AMI®,the global leader in Dynamic Firmware for worldwide computing,today announced thereleaseof AMI Data Center Manager (DCM) version 6.0. Today\'s major release delivers a
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function.
